<DOC>
	<DOCNO>NCT01888796</DOCNO>
	<brief_summary>Examination effect Linagliptin versus placebo diastolic function patient type 2 diabetes mellitus diastolic dysfunction assess transthoracic echocardiography . Furthermore effect serum level NT-pro BNP biomarker heart failure investigate .</brief_summary>
	<brief_title>Diastolic Dysfunction Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Treatment : The Patients receive Linagliptin 5 mg QD placebo period 6 month . The echocardiography 24h RR measurement perform baseline 6 month initiation therapy . The blood chemistry ( Glucose , HbA1c , BNP ) evaluate baseline well 3 6 month initiation therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>1 . Diabetes mellitus Type 2 2 . Age &gt; 50 year 3 . HbA1c &gt; 7 % 4 . Left ventricular diastolic dysfunction determine echocardiography average E/é ≥13 average E/é≥8 LA volume ≥34ml/m2 5 . Stable antidiabetic medication last 6 week include maximal tolerate dose metformin ( unless contraindication intolerance metformin exist ) . 6 . Indication increase antidiabetic medication judge investigator 7 . Written inform consent prior study participation 1 . Diabetes mellitus type 1 2 . Echocardiography : decrease leave ventricular systolic function , ejection fraction ( EF ) &lt; 45 % regional wall motion abnormality hypertrophic cardiomyopathy ( septum &gt; 15mm ) severe valvular dysfunction 3 . Uncontrolled hypertension 4 . Atrial fibrillation 5 . Obstructive sleep apnea syndrome 6 . Use DPP4 Inhibitor ( Dipeptidylpeptidase IV Inhibitor ) , GLP 1 agonist , Thiazolindinedione 7 . Kidney disease CKD 4 ( GFR &lt; 30 ml/min/1.73 ) 8 . Liver disease ( ALT AST &gt; 3 time upper limit norm ) know liver cirrhosis 9 . Active malignant disease 10 . HbA1c &gt; 8.5 % 11 . Recent ( &lt; 3 month ) clinically significant coronary cerebral vascular event 12 . Pregnant female determine positive [ serum urine ] hCG test Screening prior dosing . Participants childbearing age use adequate contraception define study protocol . 13 . Lactating female 14 . The subject history illness , , opinion Investigator , might pose unacceptable risk administer study medication . 15 . The subject receive investigational drug within 30 day prior inclusion study 16 . The subject current past medical condition and/or require medication treat condition could affect evaluation study 17 . The subject unwilling unable follow procedure outline protocol 18 . The subject mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>T2DM</keyword>
	<keyword>diastolic dysfunction</keyword>
</DOC>